ChemPartner PharmaTech Co Ltd Strategic Asset Allocation Index
ChemPartner PharmaTech Co Ltd strategic asset allocation index. ChemPartner PharmaTech Co Ltd (300149) has a Strategic Asset Allocation Index of 44.1% as of June 2023. Strategic assets (PP&E of CN¥1.05 Billion plus long-term investments of CN¥-) total CN¥1.05 Billion, measured against net assets of CN¥2.37 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. Check ChemPartner PharmaTech Co Ltd (300149) tangible equity ratio to evaluate the tangible quality of the company's equity base.
SAAI
Strategic Assets
PP&E
Net Assets
Strategic Asset Allocation Index of ChemPartner PharmaTech Co Ltd (2007–2022)
Strategic asset allocation index of ChemPartner PharmaTech Co Ltd from 2007 to 2022. This chart shows how ChemPartner PharmaTech Co Ltd's Strategic Asset Allocation Index has evolved across 16 annual periods from 2007 to 2022. As of June 2023, the index stands at 44.1%, representing strategic assets of CN¥1.05 Billion against net assets of CN¥2.37 Billion CNY.
ChemPartner PharmaTech Co Ltd Strategic Asset Allocation Index by Year (2007–2022)
ChemPartner PharmaTech Co Ltd strategic asset allocation index by year from 2007 to 2022. The table below presents the year-by-year Strategic Asset Allocation Index for ChemPartner PharmaTech Co Ltd from 2007 to 2022, covering 16 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see ChemPartner PharmaTech Co Ltd (300149) total market value.
| Year | SAAI | Strategic Assets (CNY) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 40.8% | CN¥973.62 Million | CN¥973.62 Million | CN¥- | CN¥2.39 Billion | ▼ -35.2 pp |
| 2021 | 76.0% | CN¥1.51 Billion | CN¥1.51 Billion | CN¥- | CN¥1.99 Billion | ▲ +37.4 pp |
| 2020 | 38.6% | CN¥946.13 Million | CN¥946.13 Million | CN¥- | CN¥2.45 Billion | ▲ +10.4 pp |
| 2019 | 28.1% | CN¥648.19 Million | CN¥648.19 Million | CN¥- | CN¥2.30 Billion | ▲ +2.5 pp |
| 2018 | 25.6% | CN¥564.46 Million | CN¥564.46 Million | CN¥- | CN¥2.20 Billion | ▲ +6.8 pp |
| 2017 | 18.8% | CN¥156.78 Million | CN¥156.78 Million | CN¥- | CN¥835.45 Million | ▼ -1.0 pp |
| 2016 | 19.8% | CN¥152.06 Million | CN¥152.06 Million | CN¥- | CN¥769.93 Million | ▼ -2.4 pp |
| 2015 | 22.2% | CN¥160.60 Million | CN¥160.60 Million | CN¥- | CN¥723.81 Million | ▼ -11.0 pp |
| 2014 | 33.2% | CN¥231.33 Million | CN¥231.33 Million | CN¥- | CN¥696.53 Million | ▲ +1.2 pp |
| 2013 | 32.0% | CN¥214.27 Million | CN¥214.27 Million | CN¥- | CN¥670.29 Million | ▲ +7.9 pp |
| 2012 | 24.1% | CN¥154.21 Million | CN¥154.21 Million | CN¥- | CN¥640.90 Million | ▲ +11.4 pp |
| 2011 | 12.7% | CN¥77.63 Million | CN¥77.63 Million | CN¥- | CN¥611.46 Million | ▲ +1.8 pp |
| 2010 | 10.9% | CN¥62.02 Million | CN¥62.02 Million | CN¥- | CN¥571.30 Million | ▼ -41.5 pp |
| 2009 | 52.4% | CN¥53.02 Million | CN¥53.02 Million | CN¥- | CN¥101.26 Million | ▲ +3.9 pp |
| 2008 | 48.5% | CN¥28.30 Million | CN¥28.30 Million | CN¥- | CN¥58.36 Million | ▼ -21.0 pp |
| 2007 | 69.5% | CN¥16.85 Million | CN¥16.85 Million | CN¥- | CN¥24.25 Million | — |